Anavex Life Sciences Corp is a US-based pharmaceutical company specializing in developing precise therapies for central nervous system diseases with a focus on ESG factors. Using innovative precision medicine techniques, it identifies biomarkers from genomic data to tailor treatments for patients with neurodegenerative and neurodevelopmental diseases. Their lead compound ANAVEX 2-73 targets Alzheimer's, Parkinson's, and rare CNS disorders like Rett syndrome. With a moderate risk rating score of 29.0, Anavex is dedicated to advancing novel therapies for CNS management.